Key result
Impaired endothelial nitric oxide bioavailability is linked to accelerated vascular aging, hypertension, and atherogenesis.
Why the study?
Impaired endothelial nitric oxide bioavailability is associated with aging, hypertension, and atherogenesis, but its role as a modifiable vascular risk factor in older adults is unclear.
Does pharmacotherapy aimed at improving endothelial NO bioavailability modify age-related vascular disease in older adults?
Does pharmacotherapy aimed at improving endothelial NO bioavailability modify age-related vascular disease in older adults?
Improving endothelial NO bioavailability through pharmacotherapy such as ACE inhibitors and statins may help modify age-related vascular risk.
Answers are grounded in this paper and cite their sources.
May support endothelial NO as a therapeutic target in older adults; leaves open whether pharmacotherapy modifies vascular aging.
Endothelial-derived nitric oxide (NO) is responsible for maintaining continuous vasodilator tone and for regulating local perfusion and systemic blood pressure. It also has significant antiproliferative effects on vascular smooth muscle and platelet anti-aggregatory effects. Impaired endothelial-dependent (NO mediated) vasorelaxation is observed in most animal and human models of healthy aging. It also occurs in age-associated conditions such as atherosclerosis and hypertension. Such "endotheliopathy" increases vascular risk in older adults. Studies have indicated that pharmacotherapeutic intervention with angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase inhibitors may improve NO-mediated vasomotor function. This review, evaluates the association between impaired endothelial NO bioavailability, accelerated vascular aging, and the age-associated conditions hypertension and atherogenesis. This is important, because pharmacotherapy aimed at improving endothelial NO bioavailability could modify age-related vascular disease and transform age into a potentially modifiable vascular risk factor, at least in a subpopulation of older adults.
No takes yet. Share an insight, caveat, or question.
Donnelly et al. (2008) conducted a review in Aging, hypertension, and atherogenesis. Impaired endothelial nitric oxide bioavailability was evaluated. Impaired endothelial nitric oxide bioavailability is associated with accelerated vascular aging, hypertension, and atherogenesis, suggesting it may be a modifiable vascular risk factor in older adults.
Synapse has enriched 10 related papers. Consider them for comparative context: